Clinical trial · Observational
High-Altitude Hematology Observation-Stem Cell Transplantation (HALO-SCT)
High-Altitude Hematology Observation-Stem Cell Transplantation (HALO-SCT): A Prospective Real-World Cohort Study in the Qinghai-Tibet Plateau
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The High-Altitude Hematology Observation-Stem Cell Transplantation (HALO-SCT) study is the first prospective real-world cohort of hematologic diseases and transplantation in the Qinghai-Tibet Plateau. Patients undergoing hematopoietic stem cell transplantation (HSCT) at Qinghai University Affiliated Hospital, together with their donors, are systematically enrolled. The registry collects demographic, diagnostic, treatment, prognosis, and medical expense information, as well as biospecimens for future analyses. Historical data are incorporated, and prospective data collection is ongoing with long-term follow-up planned. The registry is designed as a sustainable research infrastructure to provide comprehensive data on disease incidence, treatment patterns, outcomes, and resource utilization in a high-altitude setting.
Conditions
Conditions (15)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Acute Myeloid Leukemia (AML) | Acute Myeloid Leukemia | CURATED_BROADER | 0.80 |
| Aplastic Anemia | — | UNRESOLVED | — |
| Bleeding Disorders | — | UNRESOLVED | — |
| Bone Marrow Transplantation | — | UNRESOLVED | — |
| Hematopoietic Stem Cell Transplantation (HSCT) | — | UNRESOLVED | — |
| Hemophilia | — | UNRESOLVED | — |
| Immune Reconstitution | — | UNRESOLVED | — |
| Leukemia | Leukemia | ONTOLOGY_EXACT | 0.90 |
| Leukemias, Acute Myeloid | Acute Myeloid Leukemia |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (1)
- label
- HSCT Patients and Donors
- description
- Patients undergoing hematopoietic stem cell transplantation (HSCT) at Qinghai University Affiliated Hospital, and their related or unrelated stem cell donors. Participants are prospectively followed for clinical outcomes and biospecimen collection under real-world conditions.
Primary outcomes (1)
- measure
- Time to neutrophil engraftment
- timeFrame
- From the date of HSCT until neutrophil engraftment or death, assessed up to 60 days
- description
- Defined as the first of 3 consecutive days with absolute neutrophil count (ANC) ≥ 0.5 × 10⁹/L without primary graft failure. Patients who die without engraftment before day +60 will be censored.
Secondary outcomes (6)
- measure
- Incidence of acute GVHD
- timeFrame
- From the date of HSCT until day +100, assessed up to 100 days
- description
- Proportion of patients developing grade I-IV acute GVHD, excluding events occurring after donor lymphocyte infusion (DLI). Diagnosis and grading based on consensus criteria (e.g., MAGIC).
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: 1. Patients diagnosed with hematologic diseases who are admitted to the HSCT center of Qinghai University Affiliated Hospital on or after September 1, 2023. 2. Planned or actual hematopoietic stem cell transplantation (HSCT). 3. Provision of signed informed consent. Exclusion Criteria: 1. Inability to provide long-term follow-up data due to severe comorbidities or logistical reasons. 2. Substance abuse compromising adherence. 3. Any condition judged by investigators to jeopardize safety or compliance.
References
Publications (0)
Data not yet available